Abstract

A REVIEW ON CURRENT PROSPECT ON LAMBERT EATON MYASTHENIC

Ragini Ramprabhu Deshpande*, Om Panjabrao Akhade, Prof. P.N. Folane, Dr. K. R. Biyani and Dr. R. H. Kale

ABSTRACT

Lambert-Eaton Myasthenic Syndrome (LEMS) is a disorder of neuromuscular junction. LEMS is a rare disease including well-characterized pathogenesis. It may present as primary autoimmune disorder or paraneoplastic phenomenon. In Maximum cases, LEMS is a paraneoplastic (P-LEMS) manifestation which is link by small cell lung cancer (SCLC) and the autoimmune (A-LEMS) form includes other dysimmune diseases. In the maximum cases more than 85% of LEMS patient's antibodies present against presynaptic membrane voltage-gated calcium channels (VGCC). These antibodies are precisely involved in the pathophysiology of the disorder by which at the nerve terminal reduction in acetylcholine (ACh) occurs which leads to the muscle weakness. This article describes an overview on Lambert-Eaton Myasthenic Syndrome disorder.

Keywords: Neuromuscular disorder; muscle weakness; voltage-gated calciumchannels; amifampridine.